Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00159627 · ClinicalTrials.gov registry record · Phase 2

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

A Phase 2 study of Heart Failure, Congestive, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Completed
Registry status
Phase 2
Development phase
52
Enrollment target
10
Study locations

NCT00159627 is a Phase 2 study of Heart Failure, Congestive that has completed, run by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 52 participants, below the 640-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (92% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00159627, a Phase 2 study of Heart Failure, Congestive, has completed, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

COMPLETED
Registry status
Phase 2
Development phase
52 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.

Conditions Studied

Heart Failure, Congestive

Interventions

  • DRUG KW-3902IV

Study Locations (10)

Massachusetts

  • - Ayer
  • - Boston

California

  • - Stanford

District of Columbia

  • - Washington D.C.

Florida

  • - Sarasota

Maryland

  • - Baltimore

New Jersey

  • - Newark

Pennsylvania

  • - Philadelphia

South Carolina

  • - Charleston

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2004-08
Phase Phase 2

Sponsor

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00159627

The ClinicalTrials.gov registry entry for NCT00159627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 640-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (92% lower). The listed sponsor is NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which KW-3902IV is the first listed.

NCT00159627 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, California, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00159627 about?

NCT00159627 is a clinical study titled "Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).". The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.

What is the current status of trial NCT00159627?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-08.

What conditions does trial NCT00159627 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00159627?

The interventions under investigation include: KW-3902IV (DRUG).

Who is sponsoring clinical trial NCT00159627?

This trial is sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00159627 being conducted?

This trial has 10 study locations across California, District of Columbia, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure, Congestive

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.